Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inozyme Pharma Inc (NQ: INZY ) 5.265 +0.085 (+1.64%) Streaming Delayed Price Updated: 12:20 PM EDT, Oct 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Inozyme Pharma Inc < Previous 1 2 Next > Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors October 07, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting September 26, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference August 29, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights August 06, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function July 25, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency July 02, 2024 Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH) June 21, 2024 Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Present at the Jefferies Global Healthcare Conference May 30, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences May 23, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference May 08, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights May 07, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency April 08, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 05, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 March 26, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights March 12, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference February 26, 2024 - Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 06, 2024 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 05, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Participate in Upcoming Investor Conferences November 09, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights November 07, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 03, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 October 26, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions October 10, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting October 06, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) September 26, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023 September 20, 2023 Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2023 From Inozyme Pharma Inc. Via GlobeNewswire Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From Inozyme Pharma Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.